All In Biotech

Investigational drug · Phase 2

rapcabtagene autoleucel

Also called: YTB323

Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lupus Nephritis, Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD), ANCA Associated Vasculitis (AAV).

Phase 2

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

8

7 still active

All registered trials

9

Any phase or sponsor naming "rapcabtagene autoleucel"

First trial start

2023

Feb 28, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "rapcabtagene autoleucel", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Lupus Nephritis
  • Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
  • ANCA Associated Vasculitis (AAV)
  • Scleroderma, Diffuse
  • Idiopathic Inflammatory Myopathies
  • Progressive Multiple Sclerosis
  • Relapsing Multiple Sclerosis
  • Lupus Erythematosus, Systemic
  • Systemic Lupus Erythematosus

Approved drugs for the same conditions: Multiple sclerosis · Rheumatoid arthritis · Lupus (SLE) · Neurology · Immunology and inflammation · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "rapcabtagene autoleucel" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Lupus Nephritis

  • IanalumabVAY736, VAY736 AIPhase 318 trials

    Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome

  • hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials

    Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)

  • PovetaciceptALPN-303Phase 37 trials

    Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy

  • Rese-celCABA-201Phase 34 trials

    Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma

  • Zola-celBMS-986353, CC-97540Phase 33 trials

    Bristol Myers Squibb · Systemic Sclerosis, Lupus Erythematosus, Systemic, Lupus Nephritis

  • UC-MSCRY_SW01 cell, Human umbilical cord mesenchymal stem cellsPhase 28 trials

    Jiangsu Renocell Biotech Company · Acute Respiratory Distress Syndrome, Lupus Nephritis, Spinocerebellar Ataxia Type 1

  • IPG11406Phase 23 trials

    Nanjing Immunophage Biotech Co., Ltd · Lupus Nephritis, Moderately to Severely Active Ulcerative Colitis (UC)

  • CRC01Phase 22 trials

    Curocell Inc. · Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.